TRENTON, N.J. (AP) — In a June 10 story about diabetes treatment research, The Associated Press reported erroneously that LY2605541 is a short-acting insulin. It is a long-acting insulin.

Also, Johnson & Johnson applied for U.S. approval to sell its experimental diabetes pill canagliflozin on May 31, not May 29.

Recommended Stories

June Social Security direct payment worth $994 goes out in nine days

Third round of May Social Security payments goes out in four days

FBI launches ‘fittest agent’ competition for field offices